reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Vivos Therapeutics, Inc.

VVOS · Nasdaq

4 reporting failures in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for companies with a clean record.

$23Mpublic float
2026-10-01most recent failure
2022-11-22declared past accounts unreliable

Score over time

01234202220232024202520262022-10-01 · score 12022-08-15 filed late (10-Q) · auditor2023-01-01 · score 22022-11-22 accounts unreliable2022-08-15 filed late (10-Q) · auditor2023-04-01 · score 22022-11-22 accounts unreliable2022-08-15 filed late (10-Q) · auditor2023-07-01 · score 42023-05-15 filed late (10-Q) · auditor2023-05-09 auditor change2022-11-22 accounts unreliable2022-08-15 filed late (10-Q) · auditor2023-10-01 · score 42023-08-15 filed late (10-Q) · auditor2023-05-15 filed late (10-Q) · auditor2023-05-09 auditor change2022-11-22 accounts unreliable2024-01-01 · score 32023-08-15 filed late (10-Q) · auditor2023-05-15 filed late (10-Q) · auditor2023-05-09 auditor change2024-04-01 · score 32023-08-15 filed late (10-Q) · auditor2023-05-15 filed late (10-Q) · auditor2023-05-09 auditor change2024-07-01 · score 12023-08-15 filed late (10-Q) · auditor2025-07-01 · score 12025-06-06 auditor change2025-10-01 · score 22025-08-14 filed late (10-Q) · auditor2025-06-06 auditor change2026-01-01 · score 32025-11-14 filed late (10-Q) · auditor2025-08-14 filed late (10-Q) · auditor2025-06-06 auditor change2026-04-01 · score 42026-03-31 filed late (10-K) · acquisition or merger2025-11-14 filed late (10-Q) · auditor2025-08-14 filed late (10-Q) · auditor2025-06-06 auditor change2026-07-01 · score 42026-05-15 filed late (10-Q) · auditor2026-03-31 filed late (10-K) · acquisition or merger2025-11-14 filed late (10-Q) · auditor2025-08-14 filed late (10-Q) · auditor2026-10-01 · score 32026-05-15 filed late (10-Q) · auditor2026-03-31 filed late (10-K) · acquisition or merger2025-11-14 filed late (10-Q) · auditor

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) within the prescribed time period without undue hardship and expense because the compilation, dissemination and review of the information required to be properly presented in the Form 10-Q. As of the date hereof, the Company and its independent registered public accounting firm requires additional time to complete the review of SCN’s interim financial statements and to consolidate such financial statements into the Company’s unaudited financial statements for the quarter ended March 31, 2026. The Company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended

NT 10-Q, filed 2026-05-15 · auditor

What it filed

2026-10-01auditor changed or resigned SEC →

2026-05-15filed late (10-Q)auditor SEC →

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) within the prescribed time period without undue hardship and expense because the compilation, dissemination and review of the information required to be properly presented in the Form 10-Q. As of the date hereof, the Company and its independent registered public accounting firm requires additional time to complete the review of SCN’s interim financial statements and to consolidate such financial statements into the Company’s unaudited financial statements for the quarter ended March 31, 2026. The Company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2026-03-31filed late (10-K)acquisition or merger SEC →

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-K for the year ended December 31, 2025 (the “Form 10-K”) within the prescribed time period without undue hardship and expense because the compilation, dissemination and review of the information required to be properly presented in the Form 10-K, particularly related to the Company’s 2025 acquisition of Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”), and certain SCN-related matters. As a result, the Company requires additional time to complete its year-end financial statements and related disclosures. The Company expects to file the Form 10-K within the prescribed extension period

2025-11-14filed late (10-Q)auditor SEC →

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) within the prescribed time period. On June 10, 2025, the Company acquired Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”). As of the date hereof, the Company and its independent registered public accounting firm requires additional time to complete the review of SCN’s interim financial statements and to consolidate such financial statements into the Company’s unaudited financial statements for the quarter ended September 30, 2025. The Company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2025-08-14filed late (10-Q)auditor SEC →

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) within the prescribed time period. On June 10, 2025, the Company acquired Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”). As of the date hereof, the Company and its independent registered public accounting firm requires additional time to complete the required 2023 and 2024 audit of SCN, the review of SCN’s interim financial statements and to integrate such audited and unaudited financial statements and related pro forma information into the Company’s unaudited financial statements for the quarter ended June 30, 2025. The Company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2025-06-06auditor changed or resigned SEC →

2023-08-15filed late (10-Q)auditor SEC →

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended June 30, 2023 (the “Form 10-Q”) within the prescribed time period. The Company and its independent registered public accounting firm require additional time to review certain disclosures related to the Company’s accounting for and disclosures related to the Company’s Employee Retention Credit previously received under Section 2301 of the Coronavirus Aid, Relief, and Economic Security Act of 2020. The Company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2023-05-15filed late (10-Q)auditor SEC →

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2023 (the “Form 10-Q”) within the prescribed time period. As disclosed in its Current Report on Form 8-K filed on May 9, 2023, effective May 3, 2023, the Company dismissed its former independent registered public accounting firm, Plante & Moran, PLLC, and engaged Moss Adams LLP (“Moss Adams”) as its registered public accounting firm. As a result of the Company’s transition to a new independent registered public accounting firm, the Company and Moss Adams require additional time to complete the Company’s procedures related to the Form 10-Q and related financial statement review procedures

2023-05-09auditor changed or resigned SEC →

2022-11-22accounts declared unreliable SEC →

2022-08-15filed late (10-Q)auditor SEC →

The registrant is unable to file its Form 10-Q for the quarter ended June 30, 2022 within the prescribed time period because of ongoing analysis by the registrant and related discussions between the registrant and its registered independent registered public accountants regarding certain technical matters pertaining to the Company’s revenue recognition policies related to ASC Topic 606. The registrant is undertaking efforts with a view towards filing its Form 10-Q for the subject period within the five day grace period provided by Exchange Act Rule 12b-25

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com